Treatment and disease effects on short-term growth and adult height in children and adolescents with 21-hydroxylase deficiency.
Abstract
In clinical practice, height velocity and rate of bone maturation during each follow-up interval are among the parameters used to modify glucocorticoid treatment in children with 21-hydroxylase deficiency. There is controversy on the relative importance of treatment and disease variables for short-term growth and final height.
